Analyst Ratings February 23, 2026

Evercore ISI Lowers Arcellx Rating to In Line After Gilead Buyout

Deal at $115 per share prompts analyst downgrades and shifts valuation debate as Arcellx moves under Gilead control

By Marcus Reed ACLX GILD
Evercore ISI Lowers Arcellx Rating to In Line After Gilead Buyout
ACLX GILD

Evercore ISI cut its rating on Arcellx Inc. (NASDAQ:ACLX) to In Line from Outperform and set a $115.00 price target following Gilead Sciences' agreed acquisition of Arcellx. The all-cash offer of $115 per share plus a $5 contingent value right values the company at roughly $7.8 billion and has prompted other broker reactions, while questions about valuation and competitive dynamics persist.

Key Points

  • Evercore ISI downgraded Arcellx to In Line from Outperform and set a $115.00 price target - impacts equity analysts and biotech coverage.
  • Gilead agreed to buy Arcellx for $115 per share plus a $5 contingent value right, valuing the company at about $7.8 billion - affects M&A activity and biopharma corporate strategy.
  • Other brokers adjusted opinions: Truist cut to Hold with a $120 target, Rothschild Redburn moved to Neutral, and Stifel remained Buy citing safety data - influences investor sentiment and sector research.

Evercore ISI moved to downgrade Arcellx Inc. (NASDAQ:ACLX) to In Line from Outperform on Monday, assigning a price target of $115.00 a share.

The analyst action arrived in the wake of Gilead Sciences' announcement that it will acquire Arcellx for $115 in cash per share, along with a $5 per share contingent value right (CVR). The transaction has been reported as representing an enterprise value of roughly $7.8 billion.

The market reacted sharply to the deal. Arcellx shares jumped from a prior close of $66.53 to $113.81 on the takeover news, a move that reflects a substantial premium over the stock's trading level immediately before the announcement. At the same time, a Fair Value analysis cited in market commentary indicates the company may be overvalued at the takeover price.

Evercore ISI noted that Gilead was a logical acquirer given the two companies' existing ties. The firms already collaborate on anito-cel, and Gilead is a significant Arcellx investor, holding approximately 11.5% of the company. That relationship provided Gilead with a close perspective on the development of the anito-cel program.

Some market observers had argued that Gilead might not hasten to buy Arcellx because the partnership structure already allowed it to record partnered sales. Evercore ISI, however, said that if Arcellx were to be sold, Gilead was always the most likely buyer given the strategic alignment between the two companies.

Beyond Evercore ISI's move, several other brokerages updated their stances following the acquisition announcement. Truist Securities lowered its recommendation on Arcellx to Hold from Buy and adjusted its price target to $120, citing the acquisition's consequences for future stock value. Rothschild Redburn cut its rating to Neutral while continuing to view anito-cel's potential favorably but flagging competitive concerns. Stifel maintained a Buy rating, pointing to encouraging safety data from recent in vitro studies of anito-cel.

The deal brings several structural changes to the commercial arrangement for anito-cel. By taking full ownership, Gilead will end profit-sharing and royalty agreements tied to the program. The CVR component of the transaction provides Arcellx shareholders with potential upside contingent on achieving substantial sales milestones for the therapy.

Analysts and investors now face a set of valuation and competitive questions. The takeover price locks in a material premium for current shareholders, but some valuation metrics suggest the acquisition price may outpace the program's fair value under certain analyses. Meanwhile, the transition to full ownership by Gilead changes the incentives and revenue flows that had governed the partnered arrangement.

As Arcellx moves under Gilead's umbrella, the market will be watching how the integration affects development timelines, commercial strategy for anito-cel, and the competitive landscape for CAR T-cell therapies in multiple myeloma.

Risks

  • Valuation uncertainty - fair value analysis referenced in market commentary suggests the acquisition price may exceed intrinsic valuations, which could impact investor returns and biotech equity pricing.
  • Competitive pressure - Rothschild Redburn cited competition concerns for anito-cel, creating uncertainty for market share and revenue projections in CAR T therapies.
  • Integration and contractual changes - the end of profit-sharing and royalty deals and the shift to Gilead ownership introduces execution risk around development, commercialization and milestone realization.

More from Analyst Ratings

Monness Reaffirms Sell on Coinbase as Market Flows and Volatility Weigh on Stock Feb 23, 2026 Wolfe Research Sticks with Peerperform on PayPal as Takeover Interest Gathers Feb 23, 2026 Rosenblatt Lifts Lincoln Educational Price Target, Cites Skills Shortage and Strong Q4 Results Feb 23, 2026 Goldman Sachs Maintains Buy on Progressive, Cites Buyback Strength Amid Slower Auto Growth Feb 23, 2026 BofA Sticks With Neutral Rating on eToro, Keeps $44 Target as Analysts Reassess After Q4 Beat Feb 23, 2026